Eating disorders Mental and Behavioural Disorders
Conditions
Interventions
The VR intervention will involve sessions of up to 1 hour in length, in which the participant will use the VR café scenarios with support from the clinician. The clinician will work with the participa
Sponsors
University of Bristol
Eligibility
Sex/Gender
All
Age
14 Years to 25 Years
Inclusion criteria
Inclusion criteria: 1. Aged 14-25 years, with any eating disorder 2. Find social eating challenging 3. Currently accessing treatment for an eating disorder in a participating NHS mental health service 4. People aged 16 years or older who consent to participate 5. People aged 14-15 years old who assent to participate and for whom someone with parental responsibility consents to their participation.
Exclusion criteria
Exclusion criteria: 1. People who lack capacity to consent to participate as assessed during the consent process 2. People who are not able to travel to VR Cafe sessions 3. People who are not fluent in spoken English 4. Members of the project Patient and Public Involvement (PPI) group
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feasibility of recruitment and retention will be measured by assessing the number of potentially eligible patients in the clinical settings during the study period, the number of patients approached to participate via each recruitment route during the study period, the number of participants consenting to participate during the study period, the number of potential participants declining to participate (and reasons given) during the study period, and the number of participants who consent to participate who remain in the trial at 3-month follow-up. The Feasibility of Assessment Battery will be measured by assessing the number of participants completing all measures at baseline and the number of participants completing all measures at the end of session 1 and at 6-week and 3-month follow-ups. Feasibility of the intervention will be measured by: 1. Documenting which clinician delivers the intervention (patient’s own clinician or a member of the NHS research team with experience of working in mental health) during the study period 2. Assessing VR engagement metrics, including: 2.1. Participant goal-setting re which scenarios they want to try and how many times they want to try it, captured at the end of the study period 2.2. Number (and which) VR sessions are completed, captured at the end of the study period 2.3. Time spent using VR, captured at the end of the study period 2.4. How often scenarios are repeated, captured at the end of the study period 2.5. Whether participants and clinicians think further sessions would have been useful for each participant, captured at the end of the study period Fidelity to the treatment will be measured by asking both the participant and the clinician to complete a brief measure, documenting whether they (1) set goals in relation to the VR scenario they would try, (2) tried one or more VR scenarios, and (3) discussed the experience of completing the scenario and reviewed their goals, completed at the end of each VR session. 1. A | — |
Secondary
| Measure | Time frame |
|---|---|
| Questionnaire measures: 1. Anxiety and avoidance in relation to cafes will be measured using a bespoke questionnaire at baseline, end of VR session 1, 6 weeks after the first session, and at the 3-month follow-up 2. Self-efficacy in relation to cafes will be measured using a bespoke questionnaire at baseline, end of VR session 1, 6 weeks after the first session, and at the 3-month follow-up 3. Behaviours in relation to visiting cafés will be measured using a bespoke questionnaire at baseline, end of VR session 1, 6 weeks after the first session, and at the 3-month follow-up 4. Eating disorder symptoms will be measured by the Eating Disorder Examination Questionnaire (EDEQ) at baseline, 6 weeks after the first session, and at the 3-month follow-up 5. Symptoms of Avoidant/Restrictive Food Intake Disorder (ARFID) will be measured by the Short ARFID questionnaire at baseline, 6 weeks after the first session, and at the 3-month follow-up 6. Impact of having an eating disorder on life will be measured by the Clinical Impairment Assessment (CIA) at baseline, 6 weeks after the first session, and at the 3-month follow-up 7. General anxiety will be measured by the General Anxiety Disorder-7 (GAD-7) (18-25 year olds) or Revised Children’s Anxiety and Depression Scale (RCADS) (14-17 year olds) at baseline, 6 weeks after the first session, and at the 3-month follow-up 8. Depression will be measured by the Patient Health Questionnaire-9 (PHQ-9) (18-25 year olds) or Revised Children’s Anxiety and Depression Scale (RCADS) (14-17 year olds) at baseline, 6 weeks after the first session, and at the 3-month follow-up 9. VR side effects will be measured by the Simulator Sickness Questionnaire (SSQ) at baseline and at the end of each VR session 10. Sense of presence/place illusion will be measured at the end of the first VR session Service use measures: Service use measures will be gathered from electronic health records encompassing the study period until the 3-month follow-up: 1. Reco | — |
Countries
England, United Kingdom
Contacts
Public ContactLaura;Laura Chapman;Chapman
;
Outcome results
None listed